Form 4: Elanco Executive Ellen de Brabander Reports Stock and Option Grants

Sentiment:

SEC Form 4 Filing


Ellen de Brabander, an Executive Vice President at Elanco Animal Health, reported the grant of restricted stock units and stock options in a recent Form 4 filing.

Summary

  • Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco Animal Health Inc, filed a Form 4.
  • The filing reports the grant of 50,575 restricted stock units and 106,123 stock options on March 3, 2025.
  • The restricted stock units vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028.
  • The stock options, with an exercise price of $11.31, also vest in three equal installments on the same dates as the restricted stock units.
  • Following these transactions, de Brabander directly owns 221,740 shares of Elanco common stock and 106,123 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

  • The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders, incentivizing long-term performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Executive compensation through stock grants and options is a common practice in the animal health industry to incentivize performance and retain key personnel.

Comparison to Industry Standards

  • Stock option and restricted stock unit grants are standard compensation practices among publicly traded animal health companies such as Zoetis and IDEXX Laboratories.
  • The vesting schedules are typical, aligning with industry norms for executive compensation packages.

Stakeholder Impact

  • Shareholders may view the grants positively as they incentivize executive performance.
  • Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

DateDescription
03/03/2025Date of transaction (grant of restricted stock units and stock options)
03/03/2026First vesting date for one-third of restricted stock units and stock options
03/03/2027Second vesting date for one-third of restricted stock units and stock options
03/03/2028Final vesting date for the remaining restricted stock units and stock options
03/03/2035Expiration date of the stock options
03/05/2025Date of Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.